Search hospitals > Ohio > Belpre
Strecker Cancer Center-Belpre
Claim this profileBelpre, Ohio 45714
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
195 reported clinical trials
3 medical researchers
Summary
Strecker Cancer Center-Belpre is a medical facility located in Belpre, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Strecker Cancer Center-Belpre is involved with conducting 195 clinical trials across 370 conditions. There are 3 research doctors associated with this hospital, such as Timothy D. Moore, Thomas Moore, MD, and John P. Kuebler.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
126 reported clinical trials
208 drugs studied
Thomas Moore, MDDoctors Hospital7 years of reported clinical research
Studies Carcinoma
Studies Ductal Carcinoma
1 reported clinical trial
2 drugs studied
John P. KueblerStrecker Cancer Center-Belpre12 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Carcinoma
1 reported clinical trial
5 drugs studied
Clinical Trials running at Strecker Cancer Center-Belpre
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Bladder Carcinoma
Melanoma
Cutaneous Melanoma
Tumors
Bladder Cancer
Multiple Myeloma
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Questionnaire Choice
for Cancer Data Quality
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Recruiting1 award N/A11 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Strecker Cancer Center-Belpre?
Strecker Cancer Center-Belpre is a medical facility located in Belpre, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Strecker Cancer Center-Belpre is involved with conducting 195 clinical trials across 370 conditions. There are 3 research doctors associated with this hospital, such as Timothy D. Moore, Thomas Moore, MD, and John P. Kuebler.